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Abstract: Docetaxel (DTX) is one of the most important anticancer drugs; however, the severity 
of its adverse effects detracts from its practical use in the clinic. Magnetic nanoparticles of Fe3O4 
(MgNPs-Fe3O4) can enhance the delivery and efficacy of anticancer drugs. We investigated the 
effects of MgNPs-Fe3O4 or DTX alone, and in combination with prostate cancer cell growth 
in vitro, as well as with the mechanism underlying the cytotoxic effects. MgNPs-Fe3O4 caused 
dose-dependent increases in reactive oxygen species levels in DU145, PC-3, and LNCaP cells; 
8-hydroxydeoxyguanosine levels were also elevated. MgNPs-Fe3O4 alone reduced the viability 
of LNCaP and PC-3 cells; however, MgNPs-Fe3O4 enhanced the cytotoxic effect of a low dose 
of DTX in all three cell lines. MgNPs-Fe3O4 also augmented the percentage of DU145 cells 
undergoing apoptosis following treatment with low dose DTX. Expression of nuclear transcrip-
tion factor κB in DU145 was not affected by MgNPs-Fe3O4 or DTX alone; however, combined 
treatment suppressed nuclear transcription factor κB expression. These findings offer the pos-
sibility that MgNPs-Fe3O4–low dose DTX combination therapy may be effective in treating 
prostate cancer with limited adverse effects.
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Introduction
Prostate cancer is the most common cancer affecting men, and the second leading 
cause of cancer death in the United States.1 The incidence and mortality rates of 
prostate cancer vary greatly among different geographic areas and ethnic groups. 
Although the incidence of prostate cancer in Japan remains low compared with that in 
the United States, it has been increasing in recent years. However, by 2020, prostate 
cancer is projected to surpass stomach cancer as the most frequently diagnosed cancer 
in Japanese men.2
Several management options are available when prostate cancer is diagnosed at 
an early stage, including watchful waiting, surgery, cryosurgery, radiation therapy, 
and hormonal therapy. For advanced prostate cancers, surgical or medical ablation 
of androgens is regarded the optimal first-line treatment. In most patients treated by 
androgen deprivation, disease progression will continue until reaching a stage referred 
to as castration-resistant prostate cancer (CRPC). Progression to a hormonal refractory 
state is a complex process, involving both selection and outgrowth of preexisting 
clones of androgen-independent cells as well as adaptive upregulation of genes that 
help cancer cells survive and grow after androgen ablation.3
Although the effects of several anticancer drugs for prostate cancer have been 
evaluated in vitro and in animal experiments in vivo, most have little or no impact 
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on the survival of patients with CRPC or metastatic prostate 
cancer.4,5 Docetaxel (DTX), a semisynthetic toxoid produced 
from the needles of the European yew tree, is the first 
chemotherapy agent to improve survival in CRPC, and the US 
Food and Drug Administration has recommended a 3-week 
DTX-prednisone regimen as a first-line treatment option for 
CRPC patients.6–8 Although DTX-based chemotherapy may 
provide some benefits, most CRPC patients do not realize 
them, and the average survival remains relatively brief. 
Moreover, the current regimen requires the administration 
of high doses of DTX, which causes toxic reactions and 
thereby precludes the use of DTX as a monotherapy.9 To 
reduce toxicity and to improve the survival and quality of 
life of CRPC patients, novel therapeutic strategies targeting 
the molecular basis of androgen- and chemo-resistance of 
prostate cancer using a reduced but equieffective dose of 
DTX should be developed.
Cancer nanotechnology offers great potential for cancer 
diagnosis, targeted treatment, and monitoring.10 Researchers 
are exploring the use of nanoparticles (NPs) ranging in 
length from 1 nm to 100 nm in two or three dimensions 
to detect, image, monitor, and treat cancers. Among the 
rapidly evolving types of NPs, magnetic NPs (MgNPs) – 
biocompatible and superparamagnetic nanomaterials with 
chemical stability and low toxicity – are especially 
promising.11 The combination of MgNPs with anticancer 
agents has been applied to leukemia, lung, and pancreatic 
cancer cells in vitro and to xenograft-injected nude mice.12–15 
MgNPs composed of Fe3O4 (MgNPs-Fe3O4) are being widely 
investigated for use as targeted drug carriers. The aim of this 
study was to evaluate the effect of treatment with MgNPs-
Fe3O4 or MgNPs-Fe3O4 combined with DTX on prostate 
cancer cell growth in vitro. We also explored the mechanism 
underlying MgNPs-Fe3O4-induced cell death, focusing on 
the effect of MgNPs-Fe3O4 treatment on the production of 
reactive oxygen species (ROS).
Materials and methods
Physical characterization  
of MgNPs-Fe3O4
MgNPs-Fe3O4 were obtained from the Toda Kogyo 
Corporation (Otake, Hiroshima, Japan) and had the following 
characteristics: spherical shape; an average particle size of 
10 nm in powder and 8–10 nm as measured by transmission 
electron microscopy (TEM); a size of 60–100 nm as 
measured by dynamic light scattering (DLS); a zeta potential 
of −30 to −40 mV at a pH of 10; and a surface area in powder 
of 100–120 m2/g.
Preparation of MgNPs-Fe3O4
After ultraviolet sterilization of the particles, MgNPs-
Fe3O4 stocks were prepared by suspending particles in 
Roswell Park Memorial Institute (RPMI)-1640 with 
supplements to yield final concentrations of 1 µg/mL, 
10 µg/mL, or 100 µg/mL, followed by sonication at 30 W 
for 10 minutes with an Ultrasonic Homogenizer VP-050 
(TAITEC, Koshigaya, Saitama, Japan).
Docetaxel
DTX was purchased from Sigma-Aldrich (St Louis, MO, 
USA) and dissolved in dimethyl sulfoxide (DMSO; stock 
solution). Stock solutions were aliquoted and stored at −20°C 
to avoid repetitive freeze–thaw cycles. Stock solutions were 
serially diluted using culture medium to prepare working 
solutions.
Cell lines
LNCaP, DU145, and PC-3 human prostate cancer cell 
lines were purchased from American Tissue Type Culture 
Collection (Manassas, VA, USA). Cells were cultured in 
RPMI-1640 medium with 10% fetal bovine serum (FBS) and 
100 U/mL penicillin–streptomycin in 5% CO2 at 37°C. The 
human normal prostate stromal cell (PrSC) line was obtained 
from BioWhittaker® (Lonza Walkersville, Inc, Walkersville, 
MD, USA) and maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% FBS, 100 U/mL of 
penicillin G, 100 µg/mL of streptomycin, ITH (5 µg/mL 
insulin, 5 µg/mL transferrin, and 1.4 µmol/L hydrocortisone), 
and 5 ng/mL of bFGF in 5% CO2 at 37°C.
Characterization of MgNPs-
Fe3O4 suspension
MgNP-Fe3O4 suspensions and their cellular localization were 
characterized using the following methods.
Dynamic light scattering (DLS)
The average hydrodynamic size and size distribution of 
MgNPs-Fe3O4 in media were determined by DLS using 
a Fiber-Optics Particle Analyzer FPAR-1000 (Otsuka 
Electronics Co, Ltd, Hirakata, Osaka, Japan). DU145 cells 
were incubated with MgNPs-Fe3O4 (1 µg/mL, 10 µg/mL, or 
100 µg/mL).
Transmission electron microscopy (TEM)
DU145 cells were incubated with MgNPs-Fe3O4 (10 µg/mL). 
After incubation for 24 hours, cells were collected, washed 
three times with phosphate buffered saline (PBS), and fixed 
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with 3% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3) 
at 4°C for 4 hours. The resulting samples were postfixed with 
2% osmium tetraoxide at 4°C for 2 hours, dehydrated, and 
embedded in epoxy resin. Ultrathin sections (80 nm) were 
then stained with uranyl acetate and lead citrate, and observed 
by TEM.
Measurement of intracellular  
reactive oxygen species
ROS were measured using the CM-H2DCFDA assay 
(Life Technologies, Carlsbad, CA, USA), according to the 
manufacturer’s instructions. DU145 cells (1.0 × 105 cells/well) 
were incubated with MgNPs-Fe3O4 (1 µg/mL, 10 µg/mL, or 
100 µg/mL) for 24 hours in the absence or presence of 
N-acetylcysteine (NAC; 10 mM) (Sigma-Aldrich Co); NAC 
was added 3 hours before treatment with MgNPs-Fe3O4. 
A stock solution of CM-H2DCFDA (5 mM) was freshly 
prepared in DMSO and diluted to a final concentration of 
1 µM in PBS. Cells were washed with PBS followed by 
incubation with 50 µL of working solution of fluorochrome 
marker CM-H2 DCFDA for 30 minutes. Fluorescent 
imaging was recorded using an IX2 N-FL-1 microscope 
(Olympus Corporation, Tokyo, Japan), and analyzed using 
imaging software (Adobe Photoshop Elements 8; Adobe 
Systems Incorporated, San Jose, CA, USA). As a positive 
control, cells were treated with H2O2 (100 µM) for 24 hours.
Analysis of 8-hydroxydeoxyguanosine 
in DNA
The MgNPs-Fe3O4 (1 µg/mL, 10 µg/mL, or 100 µg/mL) 
were added to wells containing DU145, PC-3, or LNCap 
cells (5.0 × 106 cells), and incubated for 72 hours at 37°C 
(5% CO2). Nuclear deoxyribonucleic acid (DNA) of the 
cells was isolated by the sodium iodide method. Analysis 
of 8-hydroxydeoxyguanosine (8-OH-dG) was performed 
as previously described.16 The 8-OH-dG levels were 
measured by high performance liquid chromatography 
electrochemical detection. The amount of 8-OH-dG in the 
DNA was determined through comparisons with the authentic 
standards, and expressed as the number of 8-OH-dG per 106 
deoxyguanosine (dG).
AlamarBlue® assay
Cell viability was determined using the AlamarBlue® assay 
(Alamar Biosciences, Inc, Sacramento, CA, USA), according 
to the manufacturer’s instructions. Briefly, cells were seeded 
in 24-well plates (1.0 × 104 cells/well); cells were treated 
with DTX (0.1 µM, 1 µM, 10 µM, or 100 µM) or DTX 
(1 nM) plus MgNPs-Fe3O4 (1 µg/mL, 10 µg/mL, or 100 µg/
mL) for 48 hours at 37°C (5% CO2). AlamarBlue® was 
added to each well at 10% volume and was incubated for 
200 minutes. Metabolically active cells reduced the dye into a 
fluorescent form; fluorescence intensity was measured using 
a plate reader (excitation/emission: 570 nm/600 nm; Viento 
XS, DS Pharma Biomedical Co, Ltd, Suita, Osaka, Japan). 
Fluorescence intensity was used to estimate cell viability by 
linear interpolation between the emission from cells treated 
with 0.1% saponin (0% viability) and that from untreated 
cells (100% viability).
Flow cytometry (FCM) analysis 
for cell apoptosis
The apoptotic peak (sub-G1) of cells was measured using 
FCM. DU145 cells (1.0 × 106 cells) were seeded in 100 mm 
culture dishes; cells were either untreated (control), or treated 
with DTX (1 nM) or MgNPs-Fe3O4 (10 µg/mL or 100 µg/mL) 
in the absence or presence of DTX (1 nM). Aspirated medium 
was collected to determine the amount of floating cells and 
cell debris as indicators of cell death. Cells were collected 
and fixed in ice-cold 70% ethanol and stored at −20°C before 
use. In preparation for use, cells were washed with PBS and 
resuspended in PBS before incubation with ribonuclease 
(0.5 mg/mL) at room temperature for 30 minutes. After 
the addition of 1 mg/mL of propidium iodide (PI; Sigma-
Aldrich), the cells were passed through a 40 mm nylon mesh 
for analysis using an LSRII flow cytometer (BD Bioscience 
Franklin Lakes, NJ, USA). The fluorescence intensities of 
PI were measured by FCM, and the number of cells in the 
sub-G1 peak was determined. Quantification of the fraction 
was performed with ModFit LT for Mac 3.0 (Verity Software 
House, Topsham, ME, USA). 
Annexin-V assay was used to detect the early phases 
of apoptosis. Apoptosis was assessed by monitoring the 
expression of phosphatidylserine on the outer leaflet – an 
early marker of apoptotic cell death. Phosphatidylserine 
was stained with fluorescein isothiocyanate (FITC)-labeled 
Annexin V . Loss of membrane integrity as a consequence 
of necrosis was detected using PI staining of DNA. Briefly, 
DU145 cells (1.0 × 106) were either untreated (control) or 
treated with DTX (1 nM), or with MgNPs-Fe3O4 (10 µg/mL or 
100 µg/mL) for 24 hours in the absence or presence of DTX 
(1 nM). After incubation, cells were harvested, gently washed 
twice in ice-cold PBS, collected by centrifugation, and then 
stained using an Annexin V-FITC Kit (Beckman Coulter, 
Inc, Fullerton, CA, USA) according to the manufacturer’s 
instructions. Cells were then stained with Annexin V and PI 
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for analysis by FCM within 1 hour of staining using the FL1 
(FITC) and FL3 (PI) lines.
Western blot analysis
Cells were lysed in Radioimmunoprecipitation assay buffer 
(Sigma-Aldrich) containing protease inhibitors (Sigma-
Aldrich). Total protein concentration was determined by Bio-
Rad protein assay reagent (Bio-Rad Laboratories, Hercules, 
CA, USA). Equal amounts of lysates were resolved on sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and 
transferred to a polyvinylidene fluoride membrane (Merck 
Millipore, Billerica, MA, USA). Membranes were blocked 
with a blocking reagent (NOF Corporation, Tokyo, Japan) 
for 1 hour at room temperature, and incubated overnight at 
4°C with the respective primary antibodies in Tris-buffered 
saline and Tween 20 (TBST). The membranes were washed 
with TBST three times and incubated with diluted horseradish 
peroxidase-conjugated secondary antibodies (1:3000 for 
nuclear factor κB [NFκB]; 1:10,000 for β-actin) for 1 hour at 
room temperature. After three additional washes, membranes 
were detected using an enhanced chemiluminescence kit 
(GE Healthcare UK Ltd, Little Chalfont, UK). Antibodies 
against NFκB and β-actin were purchased from Santa Cruz 
Biotechnology, Inc (Santa Cruz, CA, USA) and Sigma-
Aldrich, respectively; antirabbit and antimouse horseradish 
peroxidase-conjugated secondary antibodies were purchased 
from GE Healthcare (GE Healthcare UK Ltd).
Statistical analysis
All experiments were repeated at least three times. Data are 
represented as the mean ± standard deviation. Data were 
analyzed using an unpaired Student’s t-test with or without 
Welch’s correction and ANOVA. Differences were considered 
statistically significant at P , 0.05.
Results
MgNPs-Fe3O4 characterization 
in cell culture medium
Figure 1 shows the mean hydrodynamic diameter of MgNPs-
Fe3O4 in medium with supplements as measured by DLS. The 
mean hydrodynamic diameter of MgNPs-Fe3O4 increased 
with increasing concentration, suggesting that aggregation 
is enhanced at higher concentrations.
Cellular uptake
Cellular uptake of MgNPs-Fe3O4 was evident from TEM 
microphotographs (Figure 2). MgNPs-Fe3O4 were localized 
within intracellular vesicles.
rOS production
MgNPs-Fe3O4 caused dose-dependent increases of ROS 
production in DU145 and PC-3 cells; a significant increase 
in LNCaP cells was evident only at the highest dose. 
Treatment with 100 µg/mL of MgNPs-Fe3O4 elicited a 
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Figure 1 Measurement of MgNPs-Fe3O4 size by dynamic light scattering. DU145 cells were incubated with MgNPs-Fe3O4: (A) 1 µg/mL, (B) 10 µg/mL, 
and (C) 100 µg/mL.
Abbreviation: MgNPs-Fe3O4, Fe3O4 magnetic nanoparticles.
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response comparable to that evoked by H2O2 (Figure 3). 
Among the three cell lines, ROS levels in the DU145 and PC-3 
lines were higher than that in the LNCaP line. Pretreatment 
with NAC attenuated the MgNPs-Fe3O4-induced rise in ROS 
in all three prostate cancer cell lines (Figure 3).
8-OH-dG levels in DNA
The 8-OH-dG levels in the DNA in all three prostate cancer 
cell lines increased in a dose-dependent manner (Figure 4). 
The 8-OH-dG levels of DU145 and PC-3 cells exposed to 
10 µg/mL of MgNPs-Fe3O4 were 13-fold to 14-fold greater 
than that of the untreated control cells.
Effect of MgNPs-Fe3O4, DTX, 
and MgNPs-Fe3O4–DTX combinations 
on cell viability
MgNPs-Fe3O4 alone reduced the viability of LNCaP and 
PC-3 cells, but had little or no effect on the viability of 
DU145 and PrSC cells (Figure 5). These results suggest 
that the cytotoxicity of MgNPs-Fe3O4 may be dependent 
on the cell type of the prostate cancer cell line. DTX alone 
decreased cell viability in a dose-dependent manner in all 
three cancer cell lines (Figure 6). Combined treatment 
with MgNPs-Fe3O4 and DTX enhanced the inhibitory 
effect of DTX; in PC-3 cells, 100 µg/mL of MgNPs-Fe3O4 
plus 1 nM of DTX reduced cell viability so it was similar 
to that caused by 10 nM DTX alone. These data suggest 
that MgNPs-Fe3O4 may be beneficial in reducing the DTX 
dose it may and thereby overcome the safety limitations 
of DTX.
Effect of MgNPs-Fe3O4, DTX,  
and MgNPs-Fe3O4–DTX combinations  
on cell death
An apoptotic fraction of cells containing subdiploid 
amounts of DNA was detected as a sub-G1 peak (Figure 7). 
MgNPs-Fe3O4 caused a dose-dependent increase in the 
percentage of DU145 cells in the sub-G1 fraction; similarly, 
DTX alone elicited a rise in the percentage of cells in the 
sub-G1 fraction. Combined treatment with MgNPs-Fe3O4 
plus DTX augmented the effect compared to either treatment 
alone; this enhancement was dose-dependent.
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Neither MgNPs-Fe3O4 nor DTX alone increased Annexin 
V/PI staining (Figure 8). Conversely, a significant increase 
in the percentage of apoptotic cells was observed during the 
combined treatment with NPs-Fe3O4 and DTX compared to 
the untreatment, the treatment with MgNPs-Fe3O4 alone, or 
DTX alone (P , 0.05).
Effect of MgNPs-Fe3O4 and MgNPs-
Fe3O4–DTX combinations on NFκB 
expression in DU145 cells
Treatment with MgNPs-Fe3O4 alone did not lower NFκB 
expression in DU145 cells; conversely, treatment with 
MgNPs-Fe3O4–DTX combinations inhibited NFκB 
expression in a dose-dependent manner (Figure 9).
Discussion
DTX remains the cornerstone of chemotherapy for treating 
prostate cancer when castration resistance is documented and 
secondary hormone therapy is ineffective. However, to be 
effective, DTX must be administered at such high doses that 
can induce significant toxicity.9,17 To overcome this drawback, 
combination therapies have been developed; DTX combined 
with tyrosine kinase or bcl-2 inhibitors are currently in Phase II 
studies for treating CRPC.17 Drug-delivery assemblies consisting 
of a nanocarrier, a targeting agent, and DTX have also been 
developed. For example, NC-6301 – a polymeric micelle with 
DTX – shows less toxicity than native DTX in vivo; NC-6301 
is a nanoscale drug delivery system approximately 100 nm in 
a diameter.18 In the present study, we found that DTX alone 
has a strong anticancer effect, and the cytotoxic effect of a low 
concentration (1 nM) is augmented by MgNPs-Fe3O4.
Many studies have focused on the use of NPs, especially 
MgNPs, in theranostics.10,11 Due to their biocompatibility 
and stability, iron oxide MgNPs, particularly magnetic 
Fe3O4 and its oxidized and more stable form, maghemite 
γ-Fe2O3, are superior for biomedical applications compared 
to other metal oxide NPs. Moreover, iron oxide NPs may 
have additional utility as a contrast agent in magnetic 
resonance imaging or as a carrier for drug delivery.11–15 In 
the present study, we focused on MgNPs-Fe3O4 because of 
their potential to treat CRPC. This stems from the intrinsic 
properties of the magnetic core combined with the drug 
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loading capability and the biomedical properties of MgNPs 
conferred by different surface coatings. Iron oxide MgNPs 
have also effectively been used in combination with 
chemotherapy and hyperthermia to overcome drug resistance 
in a leukemia xenograft model,19 and with doxorubicin under 
a static magnetic field to enhance the doxorubicin-mediated 
cytotoxicity of MCF-7 cells.20
Results from several studies suggest that the cytotoxic 
effects of MgNPs are dependent on the metal and target 
cell type.21,22 CuO, ZnO, and CuZnFe2O4, but not Fe2O3 or 
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Figure 7 Flow cytometry analysis of apoptosis of DU145 cells. Panels represent the following treatments: (A) untreated (control); (B) MgNPs-Fe3O4 (10 µg/mL); 
(C) MgNPs-Fe3O4 (100 µg/mL); (D) DTX (1 nM); (E) DTX (1 nM) + MgNPs-Fe3O4 (10 µg/mL); and (F) DTX (1 nM) + MgNPs-Fe3O4 (100 µg/mL). 
Notes: Cells were incubated with each condition for 24 hours. The percentage of cells in the sub-G1 phase was quantified for each plot.
Abbreviations: MgNPs-Fe3O4, Fe3O4 magnetic nanoparticles; DTX, docetaxel.
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Fe3O4, were highly toxic to the human lung epithelial cell 
line A549; CuO NPs were especially effective in inducing 
a significant increase in ROS production.21 In BRL 3A liver 
cells, only silver NPs were highly toxic; Fe3O4, tungsten, 
aluminum, and MnO2 exhibited little or no toxicity.23 
Conversely, iron oxide MgNPs caused hepatic and renal 
damage when administered to mice,22 and the reduced 
viability of J774 macrophages in vitro.24
ROS act as a second messenger in cell signaling and are 
involved in various biological processes, such as growth 
and survival in normal cells. Oxidative stress reflects a 
redox imbalance within the cells and usually results from 
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Figure 8 Effects of MgNPs-Fe3O4 and docetaxel (DTX) alone or in combination on apoptosis in DU145 cells. (A) representative FCM using Annexin V/PI staining of one set 
of triplicate experiments. N10: MgNPs-Fe3O4 (10 µg/mL); N100: MgNPs-Fe3O4 (100 µg/mL); DTX: DTX (1 nM); CB10: DTX (1 nM) + MgNPs-Fe3O4 (10 µg/mL); and CB100: 
DTX (1 nM) + MgNPs-Fe3O4 (100 µg/mL). (B) Percentages of apoptotic cells from FCM analysis. 
Notes: Data are presented as the mean ± SD of three independent experiments. results show that the combination of 10 µg/mL or 100 µg/mL of MgNPs-Fe3O4 with 1 nM of DTX 
induced significant apoptosis in DU145 cells compared to untreated cells, cells treated with 10 µg/mL or 100 µg/mL of MgNPs-Fe3O4 alone, or 1nM of DTX alone (*P , 0.05).
Abbreviations:  MgNPs-Fe3O4,  Fe3O4  magnetic  nanoparticles;  DTX,  docetaxel;  PI,  propidium  iodide;  DMSO,  dimethyl  sulfoxide;  FCM,  flow  cytometry  analysis; 
SD, standard deviation.
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Figure 9 Effects of MgNPs-Fe3O4 in the absence or presence of DTX on NFκB expression in DU145 cells. (A) Western blot analysis. (B) Densitometric analysis of NFkB/
actin expression ratio.
Notes: Cells were treated for 48 hours. The ratio of NFκB expression/actin expression represents the mean ± SD of three independent experiments. results show that 
NFkB expression decreased in DU145 cells treated with 100 µg/mL of MgNPs-Fe3O4 with 1 nM of DTX compared to untreated cells (*P , 0.05).
Abbreviations: MgNPs-Fe3O4, Fe3O4 magnetic nanoparticles; DMSO, dimethyl sulfoxide; DTX, docetaxel; NFκB, nuclear factor κB; SD, standard deviation.
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the net accumulation of intracellular ROS, which are not 
detoxified by cellular antioxidative agents.25 In cancer cells, 
the production of ROS is typically increased; since they play 
important roles in initiation, progression, and metastasis, 
ROS are considered oncogenic. However, ROS are also 
implicated in triggering cell death, including that of cancer 
cells; thus, their production is desirable in chemotherapy, 
radiotherapy, and photodynamic therapy. This dual role 
of ROS has led to the development of two paradoxical 
ROS-manipulation strategies in cancer treatment.25 One 
strategy is to treat tumor cells with antioxidants, such as 
through the dietary administration of red wine and green 
tea polyphenols to prevent cancer. The other strategy is to 
provide pro-oxidant therapy, which consists of generating 
ROS directly and inhibiting antioxidative enzyme systems 
in tumor cells. In the present study, MgNPs-Fe3O4 exhibited 
mild cytotoxicity toward PC-3 and LNCaP, but not toward 
DU145 and PrSC cells. The LNCaP and PC-3 cell lines 
have previously been reported to have unique redox state 
properties, including the production of different levels of 
oxidative damage products and antioxidant proteins; these 
differences may provide new insights into the possible uses 
and dangers of using pro-oxidants or antioxidants as cancer 
therapeutic agents.26–28 We found that the MgNPs-Fe3O4-
induced increase in ROS was most robust in the DU145 
and PC-3 cell lines; however, the levels of 8-OH-dG, an 
index of oxidative DNA damage, were comparably elevated 
in all three cell lines.
The transcription of antiapoptotic genes is activated by 
the NFκB signaling pathway, resulting in cell survival. The 
NFκB signaling pathway also plays a critical role in cancer 
development and progression, and in the development of 
tumor resistance to chemotherapy and radiation therapy,29 
particularly in the transition toward CRPC.30 Previous studies 
demonstrating a relationship between elevated NFκB and 
a worse prognosis support this notion.31,32 Thus, the NFκB 
pathway has become an important target in the development 
of novel anticancer treatments. The combination of magnetic 
NPs with either adriamycin or daunorubicin has been 
reported to increase p53 levels and decrease NFκB protein 
levels, leading to increased apoptosis in Raji lymphoma 
cells.33 In the present study, treatment with MgNPs-Fe3O4 
or DTX alone had no effect on the expression of NFκB in 
DU145 cells; however, treatment with MgNPs-Fe3O4–DTX 
combinations decreased expression in a dose-dependent 
manner. This result is unique because many NPs have 
been reported to activate the NFκB pathway via activation 
of mitogen-activated protein kinase cascades by an 
oxidative stress response.34 Thus, our results suggest that 
the decrease in NFκB expression resulting from treatment 
with MgNPs-Fe3O4–DTX combinations may be uncoupled 
from ROS generation. Although the chemical components 
involved in NFκB inhibition and ROS production have been 
identified, the contribution of MgNPs-Fe3O4 exposure to 
the mechanisms of induction and action remains unclear. 
Further studies such as those measuring NFκB DNA-binding 
activity are needed.
Conclusion
We found that MgNPs-Fe3O4 significantly increased ROS 
production in prostate cancer cell lines and induced oxidative 
DNA damage; the cytotoxic effects of MgNPs-Fe3O4 alone 
were mild. Treatment with a combination of MgNPs-Fe3O4 
and a low dose of DTX enhanced the inhibitory effect of 
DTX alone on prostate cancer cell growth in vitro, and 
also suppressed NFκB expression. These findings offer the 
possibility that MgNPs-Fe3O4 may allow the dose of DTX 
to be reduced without decreasing its antitumor activity.
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